• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Genmab A/S - American Depositary Shares (NQ: GMAB )

    20.58 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EST, Dec 26, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Genmab A/S - American Depositary Shares

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    NASDAQ:GMAB appears to be flying under the radar despite its strong fundamentals.
    Despite its impressive fundamentals, GENMAB A/S -SP ADR (NASDAQ:GMAB) remains undervalued. 
    Via Chartmill
    Looking for growth without the hefty price tag? Consider NASDAQ:GMAB.
    While growth is established for GENMAB A/S -SP ADR (NASDAQ:GMAB), the stock's valuation remains reasonable. 
    Via Chartmill
    Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
    From Genmab A/S
    Via Business Wire
    NASDAQ:GMAB stands out as a growth opportunity that won't break the bank.
    NASDAQ:GMAB, a growth stock which is not overvalued. 
    Via Chartmill
    A Closer Look at 10 Analyst Recommendations For Genmab
    Via Benzinga
    Preview: Genmab's Earnings
    Via Benzinga
    NASDAQ:GMAB: a strong growth stock preparing for the next leg up?.
    Why GENMAB A/S -SP ADR (NASDAQ:GMAB) Is a Promising High-Growth Stock in the Midst of Consolidation. 
    Via Chartmill
    Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis
    From Genmab A/S
    Via Business Wire
    Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
    From Genmab A/S
    Via Business Wire
    Why NASDAQ:GMAB Is a Standout High-Growth Stock in a Consolidation Phase.
    Why GENMAB A/S -SP ADR (NASDAQ:GMAB) Is a Promising High-Growth Stock in the Midst of Consolidation. 
    Via Chartmill
    For those who appreciate value investing, NASDAQ:GMAB is a compelling option with its solid fundamentals.
    Despite its impressive fundamentals, GENMAB A/S -SP ADR (NASDAQ:GMAB) remains undervalued. 
    Via Chartmill
    Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting
    From Genmab A/S
    Via Business Wire
    12 Analysts Have This To Say About Genmab
    Via Benzinga
    NASDAQ:GMAB qualifies as a high growth stock and is consolidating.
    GENMAB A/S -SP ADR (NASDAQ:GMAB)—Positioned as a High-Growth Stock, Ready for a Potential Breakout. 
    Via Chartmill
    NASDAQ:GMAB is an undervalued gem with solid fundamentals.
    Don't overlook GENMAB A/S -SP ADR (NASDAQ:GMAB)—it's a hidden gem with strong fundamentals and an attractive price tag. 
    Via Chartmill
    When you look at NASDAQ:GMAB, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
    GENMAB A/S -SP ADR (NASDAQ:GMAB) appears to be flying under the radar despite its strong fundamentals. 
    Via Chartmill
    Investors should take note of NASDAQ:GMAB, a growth stock that remains attractively priced.
    GENMAB A/S -SP ADR (NASDAQ:GMAB) is showing good growth, while it is not too expensive. 
    Via Chartmill
    NASDAQ:GMAB, a growth stock which is not overvalued.
    NASDAQ:GMAB is showing good growth, while it is not too expensive. 
    Via Chartmill
    Jin Medical International, Nio And Other Big Stocks Moving Lower In Monday's Pre-Market Session
    Via Benzinga
    NASDAQ:GMAB is probably undervalued for the fundamentals it is displaying.
    GENMAB A/S -SP ADR (NASDAQ:GMAB) is an undervalued gem with solid fundamentals. 
    Via Chartmill
    Don't overlook NASDAQ:GMAB—a stock with solid growth prospects and a reasonable valuation.
    Don't overlook NASDAQ:GMAB—a stock with solid growth prospects and a reasonable valuation. 
    Via Chartmill
    Expert Ratings For Genmab
    Via Benzinga
    NASDAQ:GMAB: a strong growth stock preparing for the next leg up?.
    Is GENMAB A/S -SP ADR (NASDAQ:GMAB) on the Verge of a Major Breakout as a Strong Growth Stock? 
    Via Chartmill
    NASDAQ:GMAB is showing good growth, while it is not too expensive.
    GENMAB A/S -SP ADR (NASDAQ:GMAB) is not too expensive for the growth it is showing. 
    Via Chartmill
    Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial
    From Genmab A/S
    Via Business Wire
    Decoding 10 Analyst Evaluations For Genmab
    Via Benzinga
    TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
    From Genmab A/S
    Via Business Wire
    Genmab Announces Changes to its Executive Committee
    From Genmab A/S
    Via Business Wire
    On Holding Reports Mixed Q2 Results, Joins Tencent Music Entertainment And Other Big Stocks Moving Lower In Tuesday Pre-Market Session
    Via Benzinga
    GMAB Stock Earnings: Genmab Misses EPS, Beats Revenue for Q2 2024
    GMAB stock results show that Genmab missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
    Via InvestorPlace
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.